1. Project Overview

Tendering Entity: Beijing Minhai Biotechnology Co., Ltd.

Project Name: Minhai Biologics New‑Type Vaccine International Industrial Base Construction Project – 1 Design of the R&D Pilot-Scale Workshop Laboratory

Project Address: No. 35, Simiao Road, Biomedical Industry Base, Daxing District, Beijing Number

Project Overview: The Minhai Biologics International Vaccine Industrial Base Project, invested in and constructed by Beijing Minhai Biotechnology Co., Ltd., is located at Plot 0503-039 within the Daxing Biopharmaceutical Industry Base. Plots 040, 043, and 044 are bounded as follows: to the north by Simiao Road; to the south by the planned land‑use boundary (municipal green space); to the west by Xiangrui Avenue; and to the east by Tianfu Avenue. The project is primarily intended for the research, development, and production of human vaccines.

1 Building No. ___ Construction Scale: Building footprint area 7,588.48 m² ² , with a total floor area of 53,119.36 m² ² The building has a height of 31.80 meters, with one basement level and six above-ground floors. The basement floor-to-floor height is 6.6 meters; the first through third floors are 4.5 meters high; the fourth and fifth floors are 6.0 meters high; and the sixth floor is 4.5 meters high.

Supporting utility systems:

l The power source comes from 1. The substation is designed and constructed separately by the power authority.

l Drinking water is supplied by the basement softening water treatment plant, while process water is sourced from 4. The water‑treatment stations are designed and constructed separately by the wastewater‑treatment and process‑water units.

l Hot water, chilled water, and process chilled water are supplied by chillers installed at the basement power station; equipment specifications shall be provided by the design institute.

l Industrial steam is supplied by the plant’s steam boiler and requires parameters to be provided by the design institute.

l Activated wastewater is collected centrally in the basement and routed to the waste‑liquid inactivation unit; after treatment, it is discharged into the municipal sewage network.

l Ordinary wastewater is discharged directly into the sewage network.

II. Scope of Tender

1. Minhai Biotechnology’s New Vaccine International Industrial Base Construction Project 1 The design project for the R&D pilot‑scale workshop laboratory (hereinafter referred to as “this Project”) shall include construction drawings for all disciplines except architecture, structural engineering, and standard interior fit‑out; all such drawings must bear the appropriate seals of the design firm’s qualifications and the responsible personnel.

2. Assistance is required to support the design institute designated by Party A in completing the architectural and structural construction drawings for this project.

3. It is necessary to provide the design institute designated by Party A with the energy‑related supporting requirement parameters for this project.

4. It is required to collaborate with the general contractor for fit-out design to complete this project 1. Design of all standard interior finishes, cleanroom renovations, and MEP systems—including those for general laboratories, physicochemical laboratories, biochemical laboratories, and pilot-scale production workshops—on floors 1 through 6. These systems encompass, but are not limited to: water supply, drainage, process chilled and hot water, industrial steam, electrical outlets, lighting, fire protection, laboratory gases, laboratory ventilation and exhaust systems, laboratory furniture, and laboratory equipment.

5. BIM modeling for MEP installations is required for all laboratories. Design and laboratory fit-out renderings; representative rooms should include animated walkthroughs.

6. Seamlessly coordinate with the Party A‑designated general contractor for fit‑out design to ensure the project is completed on schedule, to the required quality, and in the specified scope.

3. Quality Standards

This project is a key initiative of Beijing Municipality, and its design concept must meet the requirements of scientific rigor, human-centeredness, standardization, intelligence, and landscape integration, ensuring compliance with Level 5 standards. The overarching goal is to remain at the forefront within the year and to avoid falling behind within ten years.

The project must comply with the legal and regulatory requirements of China, the European Union, the United States, and the World Health Organization pertaining to laboratories and pharmaceutical pilot-scale manufacturing facilities; it must also meet fire safety standards and occupational health and safety requirements.

Including, but not limited to, the requirements of the following current editions of standards:

Good Manufacturing Practice for Pharmaceuticals 2010 Edition and its related appendices

GB50073 Code for Design of Clean Workshops

GB50457 Standard for the Design of Cleanrooms in the Pharmaceutical Industry

GB50591 Code for Construction and Acceptance of Cleanrooms

GBT 50314 Standard for Intelligent Building Design

BSL-2\ABSL-2 Laboratory Planning and Design

GB19489 General Requirements for Biosafety in Laboratories

GB50346 Technical Code for Biosafety Laboratory Buildings

GB50016 Code for Fire Protection Design of Buildings

GB51251 Technical Standard for Smoke Control and Exhaust Systems in Buildings

GB50209 Standard for Acceptance of Construction Quality of Building Floors

GB50210 Standard for Acceptance of Construction Quality of Architectural Decoration and Renovation Projects

GB50243 Code for Acceptance of Construction Quality of Ventilation and Air-Conditioning Engineering

JGJ91 Standard for the Design of Research Building Projects

4. Registration Instructions:

1、 Participating organizations must submit the following documents: the business license of the legal entity, qualification certificates, a certificate of the legal representative or a letter of authorization from the legal entity, and a copy of the legal representative’s ID card. All copies must be stamped with the organization’s official red seal, and the company’s registered capital must be clearly indicated.

2 Units participating in the registration must possess laboratory design qualifications, and both the registering entity and the lead design team must simultaneously demonstrate the following track record:

Design of central laboratories for national and provincial-level public institutions, BSL-2/ABSL-2 , BSL-3/ABSL-3 laboratory design.

National, provincial/ministerial-level, or Fortune Global 500 Design of the company’s biochemical, physicochemical, and biosafety laboratories.

Top 10 in China’s pharmaceutical industry Design of robust biochemical, physicochemical, and biosafety laboratories.

Provide renderings and animated walkthroughs of the aforementioned project.

3 , Registration requires providing the organization’s contact person and contact information; the contact person must be the project leader or an designated business liaison, and please provide 12 Monthly social security certificate.

4 The tendering entity will review the qualification documents submitted by registered entities, giving priority to those with relevant project experience, and will conduct further discussions and on-site inspections with the shortlisted candidates.

5 , Beijing Minhai Biotechnology Co., Ltd. was established in 2004. Year is a wholly owned subsidiary of Shenzhen Kangtai Biological Products Co., Ltd. (a publicly listed company). For more information, please visit the company’s website.

V. Registration Address:

Beijing Minhai Biotechnology Co., Ltd. (No. 35, Simiao Road, Bio‑Pharmaceutical Industry Base, Daxing District, Beijing) No.). Contact persons: Mr. Hao and Ms. Fang, New Engineering Project Department; contact numbers: 010-57864910, 57864916; email: mhzb@biominhai.com 。

VI. Registration Deadline: 2020 October 16 at 17:30.

Hereby announced!

Tendering Entity: Beijing Minhai Biotechnology Co., Ltd.

                        2020 October of the year Month 09 Day